Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
NB Private Equity Partners
2025 CMD: good returns from low-risk PE model
3rd Dec 2025
Real Estate Credit Investments (RECI)
Investor Day: opportunities aplenty
2nd Dec 2025
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
125: EIS and VC Basics: How venture capital exits work in EIS & VCTs | Kealan Doyle of Symvan Capital
Stay up-to-date with the latest research
Sign up to our newsletter
Register now for Wednesday 21 January 2026 at 12:30pm -
Event | Four distinct approaches to EIS investing: Tax Advantaged Online Forum
Life Sciences research
Diurnal Group Plc
Life Sciences
Successful DITEST Phase I trial outcome
26 Nov 2019
genedrive Plc
Life Sciences
Regulatory hurdle leaped: hearing loss assay
21 Nov 2019
Stay up-to-date with the latest research
Sign up to our newsletter
Incanthera Ltd
Life Sciences
Realising near-term value in oncology
20 Nov 2019
Advanced Oncotherapy
Life Sciences
FLASH benefits from new US reimbursement
11 Nov 2019
Diurnal Group Plc
Life Sciences
Approaching a number of near-term milestones
05 Nov 2019
Shield Therapeutics Plc
Life Sciences
More choice for clinicians and patients
30 Oct 2019
genedrive Plc
Life Sciences
Acceleration of news flow expected
28 Oct 2019
Oxford BioMedica
Life Sciences
Demanding second half
16 Oct 2019
Allergy Therapeutics plc
Life Sciences
Continuing to gain market share
26 Sep 2019
Shield Therapeutics Plc
Life Sciences
FDA approval ushers in a new era for Shield
02 Sep 2019
Advanced Oncotherapy
Life Sciences
Nearing the end-goal
By
Dr Martin Hall
08 Aug 2019
Prev
1
...
7
8
9
10
11
...
22
Next
